Shares of Capricor Therapeutics jumped +23.8% to $10.61 after new long-term clinical data showed that patients with Duchenne muscular dystrophy (DMD) — a devastating genetic disease that destroys muscles over time — experienced slower deterioration in arm and elbow function when they switched from a placebo to the company's experimental cell therapy. The data emerged at the World Muscle Society congress in Hiroshima, where extension results showed "substantially slower upper-limb deterioration" in crossover patients.
The Delayed-Start Data Gives the FDA Something New to Chew On. The late-breaking poster is titled around a "cross-phase delayed-start analysis and 2-year comparison with natural history." A delayed-start design is a powerful argument for regulators: if patients who began treatment later still improved once they got it, that suggests the drug — not chance — is responsible. Capricor submitted this 24-month extension data as part of a major amendment to its application after the July advisory committee meeting, seeking a refined indication focused on upper-limb function. The FDA's final decision is now due November 22, 2026.
A Devastating Panel Vote Still Looms Over the Stock. In July, the FDA's advisory committee voted 9-3 that the evidence did not support effectiveness for treating the heart-related component of DMD.
FDA reviewers called Capricor's key analyses "post-hoc and exploratory," and the stock cratered from $19.70 to $4.19 across two brutal sessions. Today's rally, while sharp, leaves shares roughly 70% below their April peak of $35.34. The panel vote is non-binding, but its skepticism is the elephant in the room.
Cash Buys Time, but the Burn Rate Is Steep. As of June 30, Capricor held approximately $237.9 million in cash and marketable securities.
Q2 operating expenses hit $42.9 million, producing a net loss of $40.7 million.
The company expects cash to last into late 2027, but a rejection in November would force painful choices about spending on a solo launch it has been preparing.
Short Sellers Are Deeply Exposed. About 15.58 million shares — 26.9% of the float — have been sold short, meaning today's spike likely forced some bearish traders to buy back shares, amplifying the rally. B. Riley recently upgraded Capricor to "Buy" with a consensus target around $21, roughly double the current price — but only if the FDA says yes.
The bottom line: today's data strengthens Capricor's hand, but the November decision remains a coin-flip event that will either validate or devastate a company trading almost entirely on a single drug.